The Medical Letter on Drugs and Therapeutics
Duloxetine (Cymbalta) for Fibromyalgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Duloxetine (Cymbalta– Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the first.1 Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is already marketed for treatment of depression and diabetic neuropathy.2,3

FIBROMYALGIA — A chronic disorder mainly affecting women, fibromyalgia is characterized by diffuse musculoskeletal pain and is often associated with fatigue, irritable bowel symptoms and sleep problems. It has been treated with many different drugs, including analgesics, muscle relaxants, anticonvulsants, and antidepressants, particularly the tricyclic antidepressant amitriptyline (Elavil, and others). Non-drug treatments such as exercise and cognitive behavioral therapy have also ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Duloxetine (Cymbalta) for Fibromyalgia
Article code: 1291a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian